An Alexion drug could pay dividends for new Alexion parent AstraZeneca.
The UK-based pharma giant, which acquired the drug, ALXN1840, as part of its $39 billion Alexion takeover last month, said the experimental treatment aced a late-stage trial for patients with Wilson disease.
Wilson disease, a rare genetic condition, prevents the body from eliminating copper properly. As a result, copper accumulates in the brain and other organs and can lead to liver disease and psychiatric or neurological symptoms.